Order Total (1 Item Items):
Shipping Destination:
Tulum Öner (42 results)
Skip to main search results
Search filters
Product Type
- All Product Types
- Books (42)
- Magazines & Periodicals (No further results match this refinement)
- Comics (No further results match this refinement)
- Sheet Music (No further results match this refinement)
- Art, Prints & Posters (No further results match this refinement)
- Photographs (No further results match this refinement)
- Maps (No further results match this refinement)
- Manuscripts & Paper Collectibles (No further results match this refinement)
Condition Learn more
- New (36)
- As New, Fine or Near Fine (6)
- Very Good or Good (No further results match this refinement)
- Fair or Poor (No further results match this refinement)
- As Described (No further results match this refinement)
Binding
Collectible Attributes
- First Edition (No further results match this refinement)
- Signed (No further results match this refinement)
- Dust Jacket (No further results match this refinement)
- Seller-Supplied Images (13)
- Not Print on Demand (33)
Language (1)
Free Shipping
Seller Location
Seller Rating
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Condition: New.
-
From Financialisation to Innovation in UK Big Pharma
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, GB, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Seller: Rarewaves.com USA, London, LONDO, United Kingdom
Seller rating 5 out of 5 stars
Paperback. Condition: New. The tension between innovation and financialisation is central to the business corporation. Innovation entails a 'retain-and-reinvest' allocation regime that can form a foundation for stable and equitable economic growth. Driven by shareholder-value ideology, financialisation entails a shift to 'downsize-and-distribute'. This Element investigates this tension in global pharmaceuticals, focusing on the two leading UK companies AstraZeneca and GlaxoSmithKline. In the 2000s both adopted US-style governance, including stock buybacks and stock-based executive pay. Over the past decade, however, first AstraZeneca and then GlaxoSmithKline transitioned to innovation. Critical was the cessation of buybacks to refocus capabilities on investing in an innovative drugs pipeline. Enabling this shift were UK corporate-governance institutions that mitigated US-style shareholder-value maximisation. Reinventing capitalism for the sake of stable and equitable economic growth means eliminating value destruction caused by financialisation and supporting value creation through collective and cumulative innovation. This title is also available as Open Access on Cambridge Core.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Condition: New.
-
Innovation versus Financialization in the US Pharmaceutical Industry (Elements in Corporate Governance)
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Condition: New.
-
From Financialisation to Innovation in UK Big Pharma (Elements in Reinventing Capitalism)
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Condition: New.
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Condition: As New. Unread book in perfect condition.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Language: English
Published by Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Seller: Rarewaves.com USA, London, LONDO, United Kingdom
Seller rating 5 out of 5 stars
Paperback. Condition: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Language: English
Published by Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Paperback. Condition: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Condition: As New. Unread book in perfect condition.
-
From Financialisation to Innovation in UK Big Pharma (Elements in Reinventing Capitalism)
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Seller rating 5 out of 5 stars
£ 18.13
£ 11.98 shipping
Ships from United Kingdom to U.S.A.Quantity: Over 20 available
Add to basketCondition: New. In.
-
From Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Condition: New. 2022. Paperback. . . . . . Books ship from the US and Ireland.
-
From Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
Seller rating 5 out of 5 stars
Paperback / softback. Condition: New. New copy - Usually dispatched within 3 working days.
-
Innovation Versus Financialization in the Us Pharmaceutical Industry (Elements in Corporate Governance)
Language: English
Published by Cambridge University Press -, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
paperback. Condition: New.
-
From Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline (Elements in Reinventing Capitalism)
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Condition: New.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: New.
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: New.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Paperback. Condition: Brand New. 96 pages. 6.00x0.22x9.00 inches. In Stock.
-
Innovation versus Financialization in the US Pharmaceutical Industry (Elements in Corporate Governance)
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Condition: New. 2025. paperback. . . . . . Books ship from the US and Ireland.
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: As New. Unread book in perfect condition.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: As New. Unread book in perfect condition.
-
Innovation versus Financialization in the US Pharmaceutical Industry (Paperback)
Language: English
Published by Cambridge University Press, Cambridge, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Paperback. Condition: new. Paperback. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research. The US government is negotiating with pharmaceutical companies on the price of ten drugs. This Element shows that the companies (a) should have their drug prices regulated, (b) use their profits to distribute cash dividends and stock buybacks; (c) do not rely on investment by shareholders; and (d) benefit from 'collective and cumulative learning.' Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Language: English
Published by Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Paperback. Condition: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
Condition: New. Inhaltsverzeichnis1. Introduction 2. Innovation and Competition in the Global Pharmaceutical Industry 3. The Innovation-Financialisation Tension in the Global Pharmaceutical Industry 4. AstraZeneca 5. GlaxoSmithKline 6. Explaining t.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Condition: As New. Unread book in perfect condition.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Condition: New.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
From Financialisation to Innovation in UK Big Pharma
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, GB, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Paperback. Condition: New. The tension between innovation and financialisation is central to the business corporation. Innovation entails a 'retain-and-reinvest' allocation regime that can form a foundation for stable and equitable economic growth. Driven by shareholder-value ideology, financialisation entails a shift to 'downsize-and-distribute'. This Element investigates this tension in global pharmaceuticals, focusing on the two leading UK companies AstraZeneca and GlaxoSmithKline. In the 2000s both adopted US-style governance, including stock buybacks and stock-based executive pay. Over the past decade, however, first AstraZeneca and then GlaxoSmithKline transitioned to innovation. Critical was the cessation of buybacks to refocus capabilities on investing in an innovative drugs pipeline. Enabling this shift were UK corporate-governance institutions that mitigated US-style shareholder-value maximisation. Reinventing capitalism for the sake of stable and equitable economic growth means eliminating value destruction caused by financialisation and supporting value creation through collective and cumulative innovation. This title is also available as Open Access on Cambridge Core.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: New.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: As New. Unread book in perfect condition.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Language: English
Published by Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Paperback. Condition: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
